<i>BRAF</i> V600E Is a Determinant of Sensitivity to Proteasome Inhibitors
Davide Zecchin(University College London), Federica Di Nicolantonio(Candiolo Cancer Institute)
Cited by 20
Related Papers
Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers
|Nature Communications|2015|128
European Groundshot—addressing Europe's cancer research challenges: a Lancet Oncology Commission
|The Lancet Oncology|2022|104
GNAQ/GNA11 Mosaicism Causes Aberrant Calcium Signaling Susceptible to Targeted Therapeutics
|Journal of Investigative Dermatology|2023|21
Mosaic BRAF Fusions Are a Recurrent Cause of Congenital Melanocytic Nevi Targetable by MAPK Pathway Inhibition
|Journal of Investigative Dermatology|2023|20